hepatitis C

Displaying 1 - 20 of 136

European Drugs Summer School (EDSS) 2020

This 10-day summer course prepares professionals and students to meet the complex policy challenges that face Europe in the field of drugs. Involving scientific experts from the European Monitoring...

computer simulation of a Hep C virus

Testing for drug-related infectious diseases — a crucial step towards meeting international health goals

Testing for drug-related infectious diseases among people who inject drugs (PWID) is crucial if international health targets are to be met. This is among the conclusions of a new EMCDDA report out today: Drug-related infectious diseases in Europe. The update, from the agency’s drug-related...

Drug-related infectious diseases in Europe: Update from the EMCDDA expert network, 2020

This 2020 EMCDDA update on drug-related infectious diseases aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020, while highlighting some of the current innovative responses to...

Webinar: Closing the gaps on HIV self-testing/sampling in Lithuania and Italy

This webinar, integrated in the European Testing Week 2020, presents case examples from Lithuania (Asociacija Demetra) and Italy (Arcigay) where pilot activities were undertaken through the...

Events

European Testing Week 2020

European Testing Week is a European campaign that encourages partner organisations—in community, health care and policy institutions-- throughout Europe to unite for one week twice a year to increase...

Document library

Document library

COVID-19: information for people living with viral hepatitis (WHA)

This page is being updated regularly with the latest information on COVID-19 for people living with viral hepatitis.

Document library

Document library

COVID-19: HIV prevention, treatment, care and support for people who use drugs and people in prisons (UNODC)

COVID-19 guidance published by the UNODC for people who use drugs and people in prison. Publisher's summary: All people have the right to health, even in countries under lockdown or where a state of...

Document library

Document library

Knowledge questionnaire on viral hepatitis for drug service staff

This knowledge questionnaire has been developed by the EMCDDA as part of its initiiative to increase access to hepatiitis C care through drug servies. The main aims of the knowledge questionnaire are...

Events

HCV Expert meeting ‘Scaling up action on HepC for PWID’

The EMCDDA is organising an expert meeting on Scaling up action on HepC for PWID, taking place in Lisbon in January 2020.

Document library

Document library

HCV promotional material example: Hepatitis C: The facts

The leaflet presents facts regarding hepatitis C. It includes following subjects: complication of hepatitis C, the treatment, care, pregnancy, and general information on understanding hepatitis C...

simulation of a virus

Hepatitis C

Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs in Europe, although HCV infection is both preventable and curable. Effective interventions that target the prevention of HCV transmission and the treatment of hepatitis C are needed, particularly for so-called ‘hard...

Events

Expert meeting on drug-related infectious diseases (DRID) 2019

This year's expert meeting on the drug-related infectious diseases takes place 7-8 October at the EMCDDA premises in Lisbon. Drug-related infectious diseases (DRID) are among the key health...

Events

Launch of report 'Monitoring the elimination of HCV and HBV as a public health threat among PWID in Europe' - The elimination barometer

In 2016, the World Health Assembly endorsed the first Global Health Sector Strategy on viral hepatitis. The aim of the strategy is to eliminate viral hepatitis as a major public health threat by 2030...

Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe

This technical report focuses on an elimination barometer for viral hepatitis to help countries assess progress towards eliminating hepatitis C and B among people who inject drugs (PWID). The barometer is being developed by the EMCDDA together with its expert network on drug-related infectious...

Hepatitis elimination barometer — focus of new report

The EMCDDA is working with its expert network on drug-related infectious diseases (DRID) on an ‘elimination barometer’ for viral hepatitis to help countries assess progress towards eliminating hepatitis C and B among people who inject drugs (PWID). This barometer is the focus of a new EMCDDA...

8th International Conference on Hepatitis Care in Substance Users

The International Network on Hepatitis in Substance Users (INHSU) is an international, not-for-profit, member-based organisation dedicated to scientific knowledge exchange, education, and advocacy...

Events

World Hepatitis Day

Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day. Its aim is to increase awareness and understanding of viral hepatitis and the diseases it causes.

Document library

Document library

Hepatitis C: new models of care for drugs services

Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs (PWID) in Europe, although HCV infection is both preventable and curable. Effective interventions that target the...

Hepatitis C: models of care for drug services in Europe (topic overview)

Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs (PWID) in Europe. However, currently HCV infection is both preventable and curable. The importance of targeting PWID as a key population for the elimination of hepatitis C in Europe and promoting their access to...

#WorldHepatitisDay: Supporting the HCV elimination agenda –– an EMCDDA initiative to increase access to hepatitis C care in drug services

Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day. Its aim is to increase awareness and understanding of viral hepatitis and the diseases it causes.The introduction of direct-acting antiviral (DAA) therapy has profoundly changed and improved the...

1
2
3
4
5
6
7
next ›

.

Loading